TNGX vs. EOLS, PLRX, ZNTL, ALXO, LBPH, ETNB, SAGE, PRAX, OPK, and ARQT
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Evolus (EOLS), Pliant Therapeutics (PLRX), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Longboard Pharmaceuticals (LBPH), 89bio (ETNB), Sage Therapeutics (SAGE), Praxis Precision Medicines (PRAX), OPKO Health (OPK), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Evolus (NASDAQ:EOLS) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Evolus currently has a consensus price target of $20.60, suggesting a potential upside of 61.57%. Tango Therapeutics has a consensus price target of $17.25, suggesting a potential upside of 142.79%. Given Evolus' higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Evolus.
Evolus has higher revenue and earnings than Tango Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
90.7% of Evolus shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 5.4% of Evolus shares are held by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Evolus has a net margin of -30.52% compared to Evolus' net margin of -278.55%. Tango Therapeutics' return on equity of 0.00% beat Evolus' return on equity.
In the previous week, Evolus had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 19 mentions for Evolus and 12 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.24 beat Evolus' score of 0.00 indicating that Evolus is being referred to more favorably in the media.
Evolus has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
Evolus received 328 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 71.94% of users gave Evolus an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
Summary
Evolus beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
